ReShape Lifesciences Inc. Stock

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
0.2549 USD +1.92% Intraday chart for ReShape Lifesciences Inc. +35.59% +2.08%
Sales 2024 * 9.99M Sales 2025 * 11.99M Capitalization 5.98M
Net income 2024 * -6M Net income 2025 * -5M EV / Sales 2024 * 0.6 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.5 x
P/E ratio 2024 *
-0.57 x
P/E ratio 2025 *
-0.71 x
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.92%
1 week+35.59%
1 month+45.41%
3 months+46.58%
6 months+9.54%
Current year+2.08%
More quotes
1 week
0.17
Extreme 0.1732
0.50
1 month
0.16
Extreme 0.1602
0.50
Current year
0.14
Extreme 0.1414
0.50
1 year
0.14
Extreme 0.1414
2.59
3 years
0.14
Extreme 0.1414
475.00
5 years
0.14
Extreme 0.1414
720.00
10 years
0.14
Extreme 0.1414
1 000 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20-01-31
Director of Finance/CFO 63 21-06-14
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 15-12-31
Chairman 70 15-10-31
Director/Board Member 70 21-06-14
More insiders
Date Price Change Volume
24-05-31 0.2549 +1.92% 4,594,550
24-05-30 0.2501 -10.68% 12,278,933
24-05-29 0.28 +34.74% 212,545,021
24-05-28 0.2078 +10.53% 64,674,825

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2549 USD
Average target price
1 USD
Spread / Average Target
+292.31%
Consensus